Trial Profile
Phase II Study of Amrubicin and Paclitaxel in Previously Treated Lung Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Mar 2016 Status changed from recruiting to discontinued.
- 26 May 2014 New trial record